Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Truvada (Tenofovir/FTC)

The Basics | News | Research

See also: Medication Side Effects | Drug Interactions

Show Archived (Historical) Articles

Brand Name:	Truvada
Generic Name:	Emtricitabine + tenofovir disoproxil fumarate, FTC/TDF
Adult Single Dose:	One tablet containing 200 mg FTC and 300 mg TDF (once a day)
Food & Liquid Restrictions:	None
Drug Class:	NRTI

From The Body's "Ask the Experts" Forums

Since I started Truvada + Sustiva, I've experienced itching all over my body. Is this related to the Truvada?
My doc thinks that Combivir is a better choice than Truvada, but I'm not so sure. Where do you stand in the Combivir vs. Truvada debate?
Treatment options are a large factor in my decision to move to either the U.K. or Canada. Will I be able to easily continue my regimen of Sustiva + Truvada in either place?

» More questions

The Basics

An Overview of Truvada (Tenofovir/FTC) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
FAQs About Truvada (Regularly Updated)
From The Body's "Ask the Experts" Forums
Patient Assistance Programs (Regularly Updated)
Having problems paying for Truvada? Visit Gilead's patient assistance program page.
From Gilead Sciences, Inc.
Truvada (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Patient Information About Truvada (Tenofovir/FTC) (PDF) (November 2008)
From Gilead Sciences, Inc.
Truvada (Viread + Emtriva) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Truvada (Tenofovir + Emtricitabine) (April 22, 2006)
To read PDF, click here
From AIDS InfoNet

News

Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration

Research

Topical PrEP Comparison: Tenofovir Alone May Be as Effective as Tenofovir/FTC, Study Finds (February 9, 2009)
Walid Heneine, Ph.D., explains the results of a study in macaques which found that a topical gel offered complete protection against SIV infection -- regardless of whether that gel contained tenofovir alone or tenofovir in combination with emtricitabine.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
HIV JournalView: Tenofovir + Emtricitabine + Efavirenz vs. Zidovudine/Lamivudine + Efavirenz (February/March 2006)
An important study by Joel Gallant et al demonstrates the advantage of tenofovir + FTC in first-line therapy.
From The Body PRO
Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.